Ionis Pharmaceuticals Inc

Financials

Cash from operating activities 35.89 M30.8 M274.37 M307.51 M500.95 M268.58 M 268.58 M Cash from investing activities 274.48 M194.91 M262.64 M214.13 M134.03 M277.78 M 277.78 M Cash from financing activities 596.61 M245.93 M55.3 M644.08 M478.06 M675.84 M 675.84 M Free cash flow 772 K12.9 M254.27 M279.5 M450.61 M211.5 M 211.5 M

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

IONS

Financials

Ionis Pharmaceuticals Inc

Nouvelles

L’ETF ARK de Cathie Wood achète des actions Kratos, réduit Teradyne

Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review

Ionis présente de nouvelles données sur son médicament contre l’angio-œdème héréditaire lors de l’AAAAI

Ionis presents new data on hereditary angioedema drug at AAAAI

Ionis Pharmaceuticals Stock: Digesting Recent Events (NASDAQ:IONS)

Ionis à la conférence Oppenheimer : jalons stratégiques à venir

Ionis at Oppenheimer Conference: Strategic Milestones Ahead

Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook

FDA accepts olezarsen application for severe hypertriglyceridemia

Bernstein relève l’objectif de cours d’Ionis Pharmaceuticals en vue des résultats de phase 3

Bernstein raises Ionis Pharmaceuticals price target on phase 3 outlook

Stifel relève l’objectif de cours d’Ionis Pharmaceuticals